Table 3.
Long-Term Outcomes According to Response (Optimal vs Suboptimala) to Imatinib or MMR Status at 6, 12, and 18 Months
| Result | Probability of Achieving Indicated Milestones, %, MD Anderson Cancer Center25 (N = 281) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome | 4-Year EFS | 4-Year TFS | Ever Reaching CCyR | Ever Reaching MMR | Transformation | |||||
| Response | Optimal | Suboptimal | Optimal | Suboptimal | Optimal | Suboptimal | Optimal | Suboptimal | Optimal | Suboptimal |
| Months on treatment | ||||||||||
| 6 months | 93 | 45 | 95 | 60 | 97 | 30 | 80 | 0 | 6 | 30 |
| 12 months | 96 | 87 | 96 | 93 | 72 | 18 | 82 | 39 | 5 | 5 |
| 18 months | NP | NP | NP | NP | NA | NA | NA | 66 | 4 | 5 |
| Probability of Achieving Milestone, %, MD Anderson Cancer Center32 (N = 258) | |||
|---|---|---|---|
| Outcome | Ever Reaching CCyR | Ever Reaching MMR | Event |
| Response | No CCyR | No CCyR | No CCyR |
| Months on treatment | |||
| 6 months | 57 | 43 | 34 |
| 12 months | 42 | 31 | 38 |
| Probability of Achieving Milestone at 5 Years, %, Hammersmith Hospital UK26 (N = 224) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Outcome | OS | PFS | CCyR | Loss of CCyR | ||||
| Response | Optimal | Suboptimal | Optimal | Suboptimal | Optimal | Suboptimal | Optimal | Suboptimal |
| Months on treatment | ||||||||
| 6 months | 96 | 92 | 91 | 62b | 97 | 64c | 13 | 11 |
| 12 months | 98 | 85b | 96 | 73b | 100 | 78c | 10 | 3 |
| 18 months | 100 | 98 | 97 | 97 | NA | NA | 25 | 0 |
| Probability of Achieving Milestone at 5 Years, %, GIMEMA31 (N = 559) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Outcome | EFS | FFS | CCyR | MMR | ||||
| Response | Optimal | Suboptimal | Optimal | Suboptimal | Optimal | Suboptimal | Optimal | Suboptimal |
| 12 months treatment | 85 | 42c | 92 | 49c | 98 | 85c | 96 | 81c |
| Probability of Achieving Milestone at 7 Years,%, IRIS33 (n = 476 Evaluable Patients; N = 553 Enrolled) | ||||||
|---|---|---|---|---|---|---|
| Outcome | OS | EFS | Without AP/BC | |||
| Response | MMR | No MMR | MMR | No MMR | MMR | No MMR |
| Months on treatment | ||||||
| 6 months | 90 | 89 | 85 | 84 | 96 | 93 |
| 12 months | 93 | 89 | 91 | 79b | 99 | 90b |
| 18 months | 95 | 90 | 95 | 75b | 99 | 90b |
Abbreviations: AP/BC, accelerated phase or blast crisis; CCyR, complete cytogenetic response; EFS, event-free survival; FFS, failure-free survival; GIMEMA, Group for Hematological Malignancies of the Adult; IRIS, International Randomized Study of Interferon Plus Ara-C Versus STI571; MMR, major molecular response; NA, not applicable; NP, not provided; OS, overall survival; PFS, progression-free survival; TFS, treatment-free survival; UK, United Kingdom.
Suboptimal response was defined as <partial cytogenetic response at 6 months, <CCyR at 12 months, and <MMR at 18 months; optimal response was defined as having a response that was greater than a suboptimal response.
P ≤ .05.
P < .001.